Brief: Isofol Posts New Study Results In Favor Of Arfolitixorin
July 5 (Reuters) - Isofol Medical AB (publ) ISOFOL.ST :
* AN EXTERNAL COMMITTEE OF EXPERTS HAS PERFORMED A POST HOC
PER-PROTOCOL ANALYSIS OF CLINICAL PHASE III STUDY AGENT THAT
SHOWS NEW RESULTS IN FAVOR OF ARFOLITIXORIN
Source text for Eikon: ID:nMFNbV23sf
Further company coverage: ISOFOL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Isofol Medical AB (publ)
See all newsSweden's Isofol Medical Q1 net loss widens, raises funds
Brief: Isofol Medical Q1 Net Income SEK -15.062 Million
Brief: Isofol Medical Announces Bfarm Approval Of Optimized Phase Ib/Ii Study Design
Brief: Isofol Gets Gross Proceeds Of SEK 18.9 Mln In Connection With Exercise Of Warrants And Guarantee Commitments
Brief: Isofol Secures License Rights For Arfolitixorin In Autism